Ds. Pre-treatment levels were set as 100%.<p><b>Copyright information:</b></p><p>Taken from "Plasma PCSK9 levels are significantly modified by statins and fibrates in humans"</p><p>http://www.lipidworld.com/content/7/1/22</p><p>Lipids in Health and Disease 2008;7():22-22.</p><p>Published online 11 Jun 2008</p><p>PMCID:PMC2432057.</p><p></p
<p>Subjects were divided approximately in tertiles: baseline PCSK9<40 ng/mL, 40 to <60 ng/mL, or ≥60...
Aims: To evaluate the magnitude of the effect of statin therapy on plasma proprotein convertase subt...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted inhibitor of the low-density lip...
Ds. Pre-treatment levels were set as 100%.<p><b>Copyright information:</b></p><p>Taken from "Plasma ...
S. Pre-treatment levels were set as 100%.<p><b>Copyright information:</b></p><p>Taken from "Plasma P...
Rations of simvastatin for 24 hours at 37°C. 50 μg of total cell lysates (A and C) and 100 μl cell m...
S of fenofibrate for 24 hours at 37°C. 50 μg of total cell lysates (A and C) and 100 μl cell media (...
Abstract Background Proprotein convertase subtilisin kexin-like 9 (PCSK9) is a secreted glycoprotein...
Abstract Background During the past decade, proprotein convertase subtilisin kexin type 9 (PCSK9) ha...
International audienceThe discovery of proprotein convertase subtilisin kexin 9 (PCSK9) has consider...
Therapy with PCSK9 inhibitors resulted in an overall LDL cholesterol reduction of 40%. As can be see...
International audienceABSTRACT: BACKGROUND: PCSK9 (Proprotein Convertase Subtilisin Kexin type 9) is...
<p>Numbers in columns reflect sample size per group for individuals not taking a lipid-lowering medi...
type 9 (PCSK9) is a protein convertase that posttrans-lationally promotes the degradation of the low...
Cardiovascular diseases are mostly due to unhealthy cholesterol rich diet. This becomes one of the m...
<p>Subjects were divided approximately in tertiles: baseline PCSK9<40 ng/mL, 40 to <60 ng/mL, or ≥60...
Aims: To evaluate the magnitude of the effect of statin therapy on plasma proprotein convertase subt...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted inhibitor of the low-density lip...
Ds. Pre-treatment levels were set as 100%.<p><b>Copyright information:</b></p><p>Taken from "Plasma ...
S. Pre-treatment levels were set as 100%.<p><b>Copyright information:</b></p><p>Taken from "Plasma P...
Rations of simvastatin for 24 hours at 37°C. 50 μg of total cell lysates (A and C) and 100 μl cell m...
S of fenofibrate for 24 hours at 37°C. 50 μg of total cell lysates (A and C) and 100 μl cell media (...
Abstract Background Proprotein convertase subtilisin kexin-like 9 (PCSK9) is a secreted glycoprotein...
Abstract Background During the past decade, proprotein convertase subtilisin kexin type 9 (PCSK9) ha...
International audienceThe discovery of proprotein convertase subtilisin kexin 9 (PCSK9) has consider...
Therapy with PCSK9 inhibitors resulted in an overall LDL cholesterol reduction of 40%. As can be see...
International audienceABSTRACT: BACKGROUND: PCSK9 (Proprotein Convertase Subtilisin Kexin type 9) is...
<p>Numbers in columns reflect sample size per group for individuals not taking a lipid-lowering medi...
type 9 (PCSK9) is a protein convertase that posttrans-lationally promotes the degradation of the low...
Cardiovascular diseases are mostly due to unhealthy cholesterol rich diet. This becomes one of the m...
<p>Subjects were divided approximately in tertiles: baseline PCSK9<40 ng/mL, 40 to <60 ng/mL, or ≥60...
Aims: To evaluate the magnitude of the effect of statin therapy on plasma proprotein convertase subt...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted inhibitor of the low-density lip...